Creaney Jenette, Dick Ian M, Robinson Bruce W S
National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, 35 Stirling Hwy, Crawley, 6009 Australia ; Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Verdun Ave, Nedlands, 6009 Western Australia Australia.
Curr Pulmonol Rep. 2015;4(1):15-21. doi: 10.1007/s13665-015-0106-8.
Malignant mesothelioma is an asbestos-induced, aggressive tumour with limited treatment options and very poor outcome. Currently, there are no tumour biomarkers in widespread clinical use for this disease. Soluble mesothelin is the most intensively investigated mesothelioma biomarker and has been approved by the US FDA primarily as a tool for monitoring patient response and progression. Mesothelin is elevated in the blood and effusions of patients with mesothelioma, and is rarely elevated in people with benign disease with normal renal function. However, the sensitivity of mesothelin limits its use as a stand-alone tool for the screening of the asymptomatic asbestos-exposed population-one of the primary aims of mesothelioma biomarker studies. Thus, there is an intense research effort focused on the identification of new and/or novel biomarkers for mesothelioma. Some of the challenges associated with biomarker discovery in mesothelioma are discussed.
恶性间皮瘤是一种由石棉引起的侵袭性肿瘤，治疗选择有限且预后极差。目前，针对这种疾病尚无广泛应用于临床的肿瘤生物标志物。可溶性间皮素是研究最为深入的间皮瘤生物标志物，已获美国食品药品监督管理局批准，主要作为监测患者反应和病情进展的工具。间皮瘤患者血液和积液中间皮素水平升高，而肾功能正常的良性疾病患者中间皮素很少升高。然而，间皮素的敏感性限制了其作为筛查无症状石棉暴露人群的独立工具的应用——这是间皮瘤生物标志物研究的主要目标之一。因此，目前正集中开展大量研究工作，致力于鉴定新的和/或新颖的间皮瘤生物标志物。本文讨论了间皮瘤生物标志物发现过程中面临的一些挑战。
